Malone Commercial Brokers is pleased to offer for sale a 15,059± SF, ADA-accessible building located in the city’s growing Bayside neighborhood. The building has a seven-year, full NNN lease with CVS, the national wellness chain that recently acquired Apothecary By Design, the current tenant.
141 Preble St. is quickly accessible from Interstate 295, Forest Avenue and Marginal Way. The property has 250 feet of street frontage where 3,330 cars pass by on an average day. There are 25± parking spaces on a site that is just over a half-acre.
The two-floor building has retail and office space, with a shower in the second-floor bathroom. Two new Reznor heaters are in an unfinished area of the structure and a full build-ing generator provides back-up.
The current tenant is Apothecary By Design, a local pharmaceutical center. Their specialty is providing treatments for chronic illness, working alongside healthcare professionals to provide patients with the care level that fits their unique needs.
Net operating income, based on most recent data, is $246,967.
SALE PRICE: $3.8 million
141 Preble St., Portland is listed by Joe Malone, CCIM, and Peter Harrington of Malone Commercial Brokers in Portland. Please contact Joe at 207-233-8000 or joe@malonecb.com and Peter at 207-318-8888 or peter@malonecb.com.
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less